Yuliya Linhares, MD

Articles by Yuliya Linhares, MD

Dr. Linhares on Patient-Reported Outcomes From the OUTREACH Trial in R/R LBCL

February 10th 2023

Yuliya Linhares, MD, discusses the trial design, methodology, and key efficacy and safety results from the phase 2 OUTREACH trial (NCT03744676) evaluating lisocabtagene maraleucel (liso-cel; Breyanzi) in relapsed/refractory large B-Cell lymphoma (LBCL).

Latest Updated Articles

Dr. Linhares on Patient-Reported Outcomes From the OUTREACH Trial in R/R LBCL
February 10th 2023

Yuliya Linhares, MD

Articles by Yuliya Linhares, MD

Dr. Linhares on Patient-Reported Outcomes From the OUTREACH Trial in R/R LBCL

Latest Updated Articles

Trending on OncLive

Docetaxel Remains Unbeaten in Immunotherapy-Refractory NSCLC

Long-Term Data Refine the Role of Immunotherapy Across Early-Stage NSCLC Settings

Ris-Rez Meets Phase 3 Efficacy End Point for R/R Osteosarcoma

Cretostimogene Grenadenorepvec Elicits Durable Complete Responses and Bladder Preservation in BCG-Unresponsive NMIBC

Dr Tarantino on the Evolution of TROP2-Directed ADCs in First-Line TNBC